A new study led by the University of Miami Miller School of Medicine’s Kirill Martemyanov, Ph.D., and international collaborators highlights a new approach to treating depression that bypasses many limitations of traditional antidepressants. The team has developed a highly selective protein-based biologic called a nanobody that targets a newly discovered brain receptor implicated in depression.